Niu L.,Fuda Cancer Hospital |
Niu L.,Fuda Oncological Cryotherapy Research Institute |
He L.,Fuda Cancer Hospital |
He L.,Fuda Oncological Cryotherapy Research Institute |
And 10 more authors.
Cryobiology | Year: 2012
Objective: To assess the safety and feasibility of percutaneous cryoablation on pancreatic cancer via ultrasonography (US) and computed tomography (CT) guidance. Materials and methods: This retrospective review was approved by the institutional review board and of informed consent. Thirty-two patients (18 men and 14 women; median age 62; age range, 30-77. years) with pancreatic cancer (stage II/III/IV, 3/11/18) treated with percutaneous US and CT guided cryoablations between February 2009 and February 2010 were eligible for this review. Thirteen tumors in pancreatic head and 19 in pancreatic body and/or tail measuring 2-11. cm (mean, 5.2. cm ± 8 [standard deviation]) were ablated with 49 procedures in total. Feasibility was analyzed by enhanced CT 1-3. months post procedure and safety was assessed by clinical signs, symptoms and laboratory results. Results: Neither procedural death nor serious complications occurred. Fifteen tumors (46.9%) smaller than 5. cm were successfully ablated by one session of cryoablation. Twenty-seven patients experienced a 50% reduction in pain score, 22 experienced a 50% decrease in analgesic consumption and 16 experienced a 20 increase in Karnofsky Performance Status (KPS) Score. Partial response (PR) and stable disease (SD) turned up in 9 and 21 patients, respectively, lesions in whom were identified controlled by none enhancement on enhanced CT. Mean and median survival was 15.9 and 12.6. months, respectively. The 6-, 12- and 24-month survival rates were 82.8%, 54.7% and 27.3%, respectively. Conclusion: US and CT guided percutaneous cryoablation is a safe and promising local treatment for pancreatic cancer. © 2012 Elsevier Inc.